


Alizapride

Cat. No.:	HY-A0125
CAS No.:	59338-93-1
Molecular Formula:	C ₁₆ H ₂₁ N ₅ O ₂
Molecular Weight:	315.37
Target:	Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Alizapride is a potent antiemetic, acting as a dopamine receptor antagonist. Alizapride also used in human digestive disorders ^{[1][3]} .	
IC₅₀ & Target	Dopamine 2 receptor	
In Vivo	Alizapride (2.5, 5, 10, 25 µg/kg; SC; 7 consecutive days) significantly reduces the bound IgG-sensitized erythrocytes with Splenic macrophages isolated from animals ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Duncan–Hartley guinea pigs ^[2]
	Dosage:	2.5, 5, 10, 25 µg/kg
	Administration:	Alizapride (2.5, 5, 10, 25 µg/kg; SC; 7 consecutive days)
	Result:	Reduced the clearance of IgG-sensitized RBCs.

REFERENCES

- [1]. P L Warzee, et al. Manometric study of the activity of alizapride on the motor function of the human sphincter of Oddi. *J Clin Pharm Ther.* 1988 Aug;13(4):281-4.
- [2]. Gomez, et al. Macrophage Fcγ receptors expression is altered by treatment with dopaminergic drugs. *Clinical immunology (Orlando, Fla.)* vol. 90,3 (1999): 375-87.
- [3]. Seng, et al. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study. *British journal of clinical pharmacology* vol. 38,3 (1994): 282-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA